risedronic acid has been researched along with Cafe-au-Lait Spots with Pulmonic Stenosis in 1 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Despite the lack of consensus on the treatment of osteoporosis in NF1, risedronate may hold a promise as a potential therapy for osteoporosis complicating NF1." | 1.42 | Risedronate therapy for neurofibromatosis Type 1-related low bone mass: a stitch in time saves nine. ( Benlidayi, IC; Kozanoglu, E; Ortac, EA, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benlidayi, IC | 1 |
| Ortac, EA | 1 |
| Kozanoglu, E | 1 |
1 other study available for risedronic acid and Cafe-au-Lait Spots with Pulmonic Stenosis
| Article | Year |
|---|---|
Risedronate therapy for neurofibromatosis Type 1-related low bone mass: a stitch in time saves nine.
Topics: Adult; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Humans; Male; Neurofibromatos | 2015 |